Marumae <6264>: 1,953 yen (-147 yen).
It fell significantly due to sluggish growth. The third quarter financial results were announced last weekend, with cumulative operating profit of 20 million yen, a significant decline of 96.9% from the same period last year. The period from March to May turned into an operating profit of 100 million yen, and the achievement rate of the annual plan of 80 million yen and a 91.0% decrease from the previous year is increasing. However, positive impact seems to be limited since expectations of performance recovery as a semiconductor-related company are already taken into account. In addition, cumulative orders decreased by 11.2% compared to the same period last year, but an improvement trend has been observed since a decrease of 30.4% in the first half of the year.
Adastria <2685>: 3,295 yen (-340 yen).
It fell significantly. First quarter financial results were announced last weekend, with operating profit decreased by 4.2% compared to the same period last year to 6.01 billion yen. The annual forecast remains unchanged at 19 billion yen, a 5.5% increase from the previous year, but there is a possibility that negative views on decrease in profits will precede. Although sales remained strong, it seems that gross profit margin decreased due to the influence of the weak yen. In addition, BuzzWit, an EC-only company, seems to have reduced revenue and profits due to the struggle of its main brand, which weighed heavily on some subsidiaries.
Takashimaya <8233>: 2,921.5 yen (+214 yen).
Significantly continued to rise. The company announced its first quarter financial results last weekend, with operating profit of 17.3 billion yen, an increase of 56.7% compared to the same period last year. The first half of the year has raised financial estimates from the previous 23.6 billion yen to 27.7 billion yen, an increase of 33.4%. The full year has also been revised upward from 50 billion yen to 55 billion yen, an increase of 19.7% compared to the previous year. The increase in inbound revenue from domestic department stores seems to be a contributing factor to the better-than-expected results. J Front and the company's strong earnings have led to strong movements in department store stocks today.
J.Front <3086>: 1,891.5 yen (+214 yen).
It rose significantly. First quarter financial results were announced last weekend, with operating profit of 16.1 billion yen, an increase of 58.7% from the same period last year, which is considered to have exceeded the market expectation by about 4 billion yen. The company has revised its annual forecast upward from the previous 375 billion yen to 415 billion yen, a 3.6% decrease from the previous year, reflecting the upward trend in the first quarter. Tax-free sales seem to be progressing better than expected. There is a possibility that the expectation of business upswing will lead to expansion of shareholder return.
Nagano Keiki <7715>: 3,440 yen (+490 yen).
Temporary suspension of trading. Ichiyoshi Securities has assigned a new rating of "A" and a fair value of 5,400 yen. They expect and evaluate the company to have medium-term growth as a manufacturer of semiconductor manufacturing equipment parts, as well as a company that can enjoy the benefits of semiconductor factory construction mainly in Japan. It seems that the stock market's evaluation is still insufficient. In addition to the sustained expansion of the semiconductor manufacturing equipment market, it is expected that pressure sensors will contribute to medium-term revenue growth, as potential new customers begin to be developed.
Integ Group <192A>: 6,300 yen (-890 yen).
Stock code 7776, Selseed, increased by 80 points to 434. Stock code 4882, Perseus, also rose by 80 points to 519. Both stocks have hit their daily limit. After the end of transactions on 28th May, the company announced that Phase 1 trials of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody under development, in patients with true polycythemia (PV) had been completed. The test of the sixth and final patient was terminated by the patient's own intention, and the study ended after completing the mandated observations. The company states that there were no serious adverse events reported that raised safety concerns and that there are no changes in the outcome plan, such as the impact on performance this year or by the end of March 2025.
Cellseed <7776>: 434 yen (+80 yen).
After the close of trading on the 28th, the stock hit its daily upward limit, reaching a new high for the year. The company announced that its patent application for a cartilage cell sheet under development in the United States has been approved, which is considered a positive development. The patent is the result of joint research on the same type of cartilage cell sheet conducted by Professor Masato Sato of the Department of Orthopedics, Faculty of Medicine, School of Medicine, Tokai University. The cell sheet for the treatment of degenerative knee joint disease currently under development uses the same type of cartilage cell sheet derived from cartilage tissue collected from patients with polydactyly (a disease where the patient is born with more than 5 fingers or toes) based on the manufacturing method of this patent.
Perseus <4882>: 519 yen (+80 yen).
Marked rebound. After the end of trading on the 28th, it was announced that the phase I trial of the developing anti-transferrin receptor 1 (TfR1) antibody "PPMX-T003" for patients with true polycythemia vera (PV) has ended. At the request of the sixth and last patient, the trial was terminated and the study was completed after the required observations. No reports of serious adverse events that could jeopardize safety have been made, and there are no changes to this year's performance or the derived plan until the end of March 2025.